Zhejiang Xinguang Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2019
April 28, 2019 at 05:46 pm
Share
Zhejiang Xinguang Pharmaceutical Co., Ltd. announced earnings results for the first quarter ended March 31, 2019. For the first quarter, the company announced sales was CNY 85.070 million compared to CNY 84.335 million a year ago. Operating income was CNY 38.325 million compared to CNY 38.575 million a year ago. Net income was CNY 32.569 million compared to CNY 32.952 million a year ago. Basic earnings per share from continuing operations was CNY 0.2 compared to CNY 0.21 a year ago.
Zhejiang Xinguang Pharmaceutical Co Ltd is a China-based company mainly engaged in the research, development, production and sales of Chinese patent medicines, chemical medicines and health foods. The Company's main products are Huangqishengmaiyin, Shenjindan Capsules, American Ginseng Oral Liquid and other products. The treatment scope is mainly cardiovascular and cerebrovascular diseases, trauma diseases, and covers respiratory system, digestive system, urinary system, pediatric diseases and improving immunity. The Company operates its businesses mainly in domestic markets, with Zhejiang Province as its major market.